Home / Supplements /
\u201CNootropic\u201D as a term
This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.
Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026
“Nootropic” was coined in 1972 by the Romanian chemist and psychologist Corneliu Giurgea to describe a narrow class of compounds meeting five specific criteria. It has since drifted into a broad marketing category applied to almost any substance sold for cognitive benefit, which is why the word itself now carries very little information about what a product actually does.
On this page
Giurgea's 1972 coinage
Giurgea introduced the term after his work on piracetam, a compound he had helped develop, combining the Greek nous (mind) and trepein (to bend or turn). He proposed it as a category for compounds that acted on cognition through a specific, defined mechanism, distinct from stimulants or sedatives.
The five criteria
Giurgea proposed that a true nootropic should meet five conditions:
| Criterion | Description |
|---|---|
| Enhances learning and memory | Measurable improvement in acquisition and recall |
| Protects the brain | Resilience against physical or chemical injury (hypoxia, toxins) |
| Works through natural regulatory mechanisms | Modulates the brain's own control systems rather than overriding them |
| Lacks typical sedative or stimulant profile | No classic sedation, stimulation, or motor effects at effective doses |
| Very low toxicity | Minimal side effects, even at high doses, with few or no serious adverse effects |
Giurgea 1972/1982, as summarised in later reviews of the nootropic concept.
How the term drifted
Piracetam and a small family of structurally related compounds (the racetams) were the original referents. Over subsequent decades, marketing usage broadened the label to cover an unrelated range of products: prescription stimulants, amino acids, B-vitamins, herbal extracts, and blended supplement formulas sold under the umbrella term. Most of these do not meet Giurgea’s original criteria — many have clear stimulant or sedative profiles, or have not been assessed for the neuroprotective and low-toxicity criteria he specified.
Why the term now carries little information
Because “nootropic” is applied to chemically and pharmacologically unrelated substances with different mechanisms, different evidence bases, and different risk profiles, the label itself predicts almost nothing about a given product’s effect, dose, or safety. Two products both marketed as “nootropics” can differ as much from each other as either does from a substance never called one.
What to ask instead
A more useful question replaces the category label with four specifics: what compound, exactly; at what dose; what outcome is claimed; and how was that outcome measured — in a controlled trial with a defined battery, or in self-report. Those four answers carry the information the word “nootropic” no longer does.
Who coined the term nootropic?
Romanian chemist and psychologist Corneliu Giurgea, in 1972, to describe piracetam and compounds he believed shared its specific properties.
What were Giurgea's original criteria?
Broadly: enhancing learning and memory, protecting the brain against damage, working through the brain’s own regulatory mechanisms, lacking typical sedative or stimulant side effects, and having very low toxicity.
Why does the term now carry little information?
It has been applied to an increasingly broad range of unrelated substances — prescription stimulants, amino acids, herbal extracts, vitamins — most of which do not meet Giurgea’s original criteria.
What should someone ask instead of "is this a nootropic"?
What specific compound, at what dose, produces what specific outcome, and how was that outcome measured.